<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006542</article-id><article-id pub-id-type="pmc">PMC11859373</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics17020175</article-id><article-id pub-id-type="publisher-id">pharmaceutics-17-00175</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Mechanistic Investigation into Crystallization of Hydrated Co-Amorphous Systems of Flurbiprofen and Lidocaine</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0418-6749</contrib-id><name><surname>Xu</surname><given-names>Xiaoyue</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-pharmaceutics-17-00175" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0482-1397</contrib-id><name><surname>Grohganz</surname><given-names>Holger</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-pharmaceutics-17-00175" ref-type="aff">1</xref><xref rid="c1-pharmaceutics-17-00175" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3736-8098</contrib-id><name><surname>Knapik-Kowalczuk</surname><given-names>Justyna</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af2-pharmaceutics-17-00175" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Paluch</surname><given-names>Marian</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af2-pharmaceutics-17-00175" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7521-6020</contrib-id><name><surname>Rades</surname><given-names>Thomas</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-pharmaceutics-17-00175" ref-type="aff">1</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Kachrimanis</surname><given-names>Kyriakos</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Timmins</surname><given-names>Peter</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-17-00175"><label>1</label>Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark<email>thomas.rades@sund.ku.dk</email> (T.R.)</aff><aff id="af2-pharmaceutics-17-00175"><label>2</label>SMCEBI, Institute of Physics, Faculty of Science and Technology, University of Silesia in Katowice, 75 Pu&#x00142;ku Piechoty 1a, 41-500 Chorz&#x000f3;w, Poland</aff><author-notes><corresp id="c1-pharmaceutics-17-00175"><label>*</label>Correspondence: <email>holger.grohganz@sund.ku.dk</email></corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>175</elocation-id><history><date date-type="received"><day>11</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>21</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>27</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background:</bold> It is generally accepted that water as a plasticizer can decrease the glass transition temperatures (T<sub>g</sub>s) of amorphous drugs and drug delivery systems, resulting in physical instabilities. However, a recent study has reported an anti-plasticizing effect of water on amorphous lidocaine (LID). In co-amorphous systems, LID might be used as a co-former to impair the plasticizing effect of water. <bold>Method:</bold> Flurbiprofen (FLB) was used to form a co-amorphous system with a mole fraction of LID of 0.8. The effect of water on the stability of co-amorphous FLB-LID upon hydration was investigated. The crystallization behaviors of anhydrous and hydrated co-amorphous FLB-LID systems were measured by an isothermal modulated differential scanning calorimetric (iMDSC) method. The relaxation times of the co-amorphous FLB-LID system upon hydration were measured by a broadband dielectric spectroscopy (BDS), and the differences in Gibbs free energy (&#x00394;G) and entropy (&#x00394;S) between the amorphous and crystalline phases were determined by differential scanning calorimetry (DSC). <bold>Results:</bold> It was found that the crystallization tendency of co-amorphous FLB-LID decreased with the addition of water. Molecular mobility and thermodynamic factors were both investigated to explain the difference in crystallization tendencies of co-amorphous FLB-LID upon hydration. <bold>Conclusions:</bold> The results of the study showed that LID could be used as an effective co-former to decrease the crystallization tendency of co-amorphous FLB-LID upon hydration by enhancing the entropic (&#x00394;S) and thermodynamic activation barriers (T&#x00394;S)<sup>3</sup>/&#x00394;G<sup>2</sup>) to crystallization.</p></abstract><kwd-group><kwd>co-amorphous</kwd><kwd>crystallization</kwd><kwd>thermodynamics</kwd><kwd>anti-plasticizing</kwd><kwd>effect of water</kwd><kwd>lidocaine</kwd></kwd-group><funding-group><award-group><funding-source>China Scholarship Council</funding-source><award-id>202008420212</award-id></award-group><funding-statement>This research was funded by the China Scholarship Council, grant number 202008420212.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-17-00175"><title>1. Introduction</title><p>In the formulation of poorly water-soluble drugs, there is increasing interest in utilizing an amorphous form of the active pharmaceutical ingredient (API) rather than its crystalline counterpart due to the inherent dissolution rate enhancement and solubility improvement of the amorphous form [<xref rid="B1-pharmaceutics-17-00175" ref-type="bibr">1</xref>]. However, the absence of crystalline lattice renders amorphous drugs and systems intrinsically unstable, resulting in crystallization [<xref rid="B2-pharmaceutics-17-00175" ref-type="bibr">2</xref>]. Co-amorphous systems are thus developed as a formulation strategy to stabilize the amorphous API against crystallization through the use of a low molecular weight co-former, which could be either an inactive ingredient or another API [<xref rid="B3-pharmaceutics-17-00175" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceutics-17-00175" ref-type="bibr">4</xref>].</p><p>The crystallization of amorphous drugs and co-amorphous systems is governed by nucleation and crystal growth, which are influenced by the combined effects of kinetics (such as molecular mobility) and thermodynamics (such as enthalpy, entropy, and Gibbs free energy) [<xref rid="B5-pharmaceutics-17-00175" ref-type="bibr">5</xref>]. The global molecular mobility, usually referred to as &#x003b1;-relaxation, resulting from long-range cooperative motions of molecules, is responsible for the glass transition. It is generally accepted that enhanced global molecular mobility could kinetically promote the crystallization process of amorphous drugs [<xref rid="B6-pharmaceutics-17-00175" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceutics-17-00175" ref-type="bibr">7</xref>]. In addition, the Johari&#x02013;Goldstein (&#x003b2;) relaxation has been shown to have a strong correlation with the physical instability of amorphous drugs [<xref rid="B7-pharmaceutics-17-00175" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceutics-17-00175" ref-type="bibr">8</xref>]. However, molecular mobility is not the only factor associated with the stability of amorphous drugs and drug formulations. Previous studies have highlighted the significance of thermodynamics in influencing the crystallization of amorphous drugs and co-amorphous systems. In 2022, Kumar and Suryanarayanan explained the observed differences in the stability of amorphous drugs in terms of the thermodynamic activation barriers for a range of drugs, including nifedipine, indomethacin, felodipine, and ketoconazole [<xref rid="B9-pharmaceutics-17-00175" ref-type="bibr">9</xref>]. Furthermore, previous studies have identified the role of configurational entropy in stabilizing amorphous drugs and co-amorphous systems [<xref rid="B10-pharmaceutics-17-00175" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-17-00175" ref-type="bibr">11</xref>]. These findings suggest that both molecular mobility and thermodynamic factors play an important role in the crystallization process.</p><p>Previous observations on glassy materials indicate changes in mechanical properties, such as the modulus of a polymer at or near room temperature due to the addition of plasticizers and anti-plasticizers [<xref rid="B12-pharmaceutics-17-00175" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceutics-17-00175" ref-type="bibr">13</xref>]. Specifically, the physical stability of amorphous drugs and co-amorphous systems is known to be sensitive to the addition of water due to its plasticizing effect [<xref rid="B14-pharmaceutics-17-00175" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceutics-17-00175" ref-type="bibr">15</xref>]. The plasticizing effect of water on amorphous formulations can facilitate the crystallization process by decreasing their glass transition temperatures (T<sub>g</sub>s) and increasing molecular mobility [<xref rid="B16-pharmaceutics-17-00175" ref-type="bibr">16</xref>]. The adsorption of water introduces excess free volume into amorphous drugs and co-amorphous systems, leading to a higher thermodynamic driving force for crystallization [<xref rid="B14-pharmaceutics-17-00175" ref-type="bibr">14</xref>].</p><p>The term anti-plasticizer is used in this study to indicate a molecule with a lower T<sub>g</sub> than the drug that nonetheless increases the T<sub>g</sub> of that drug when being a part of the amorphous system [<xref rid="B17-pharmaceutics-17-00175" ref-type="bibr">17</xref>]. Although water is generally observed to act as a plasticizer in amorphous pharmaceuticals, it has been shown to have an anti-plasticizing effect on certain drugs and polymers [<xref rid="B17-pharmaceutics-17-00175" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-17-00175" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceutics-17-00175" ref-type="bibr">19</xref>]. The mechanism of the anti-plasticizing effect of water is still under investigation and is being studied based on the structural properties of amorphous materials [<xref rid="B20-pharmaceutics-17-00175" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceutics-17-00175" ref-type="bibr">21</xref>]. Some recent studies have found that water could also have an anti-plasticizing effect on some amorphous drugs, including prilocaine (PRL) and lidocaine (LID), resulting in increased T<sub>g</sub>s of PRL and LID upon hydration [<xref rid="B17-pharmaceutics-17-00175" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-17-00175" ref-type="bibr">18</xref>]. The T<sub>g</sub>s of hydrated PRL and LID exhibited maximum increases in the T<sub>g</sub>s of 4.1 K and 0.9 K, respectively, in comparison to their anhydrous counterparts [<xref rid="B18-pharmaceutics-17-00175" ref-type="bibr">18</xref>]. The anti-plasticizing effect of water was found to be associated with the hydrogen bonding pattern between water and the carbonyl groups of PRL and LID [<xref rid="B17-pharmaceutics-17-00175" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-17-00175" ref-type="bibr">18</xref>,<xref rid="B22-pharmaceutics-17-00175" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceutics-17-00175" ref-type="bibr">23</xref>]. Furthermore, previous work indicated that water could maintain an anti-plasticizing effect on co-amorphous systems of PRL and LID at various mole fractions of PRL [<xref rid="B18-pharmaceutics-17-00175" ref-type="bibr">18</xref>]. These findings suggest that PRL and LID could be used as potential co-formers to impair the plasticizing effect of water in other co-amorphous systems. It was found that the effect of water on co-amorphous systems of nicotinamide (NIC) and PRL was correlated with the mole fractions of PRL. The anti-plasticizing effect of water could still be maintained at mole fractions of PRL of 0.8 and above, with increased T<sub>g</sub>s and reduced mobility upon hydration [<xref rid="B24-pharmaceutics-17-00175" ref-type="bibr">24</xref>].</p><p>FLB was used as a model drug in this study due to its co-formability with LID [<xref rid="B2-pharmaceutics-17-00175" ref-type="bibr">2</xref>]. Since the &#x00394;pKa between FLB (pKa = 4.42) [<xref rid="B25-pharmaceutics-17-00175" ref-type="bibr">25</xref>] and LID (pKa = 7.91) [<xref rid="B26-pharmaceutics-17-00175" ref-type="bibr">26</xref>] exceeds three, proton transfer (i.e., ionic interactions) is likely [<xref rid="B27-pharmaceutics-17-00175" ref-type="bibr">27</xref>]. A high degree of proton transfer between FLB and LID could alter the hydrogen bonding pattern between water and the co-former LID, leading to a plasticizing effect of water on the ionized LID. However, studies have shown that the molecular interactions between FLB and LID were primarily governed by hydrogen bonding (&#x0003e;99%) at a mole fraction of LID of 0.5 [<xref rid="B28-pharmaceutics-17-00175" ref-type="bibr">28</xref>], facilitated by the tertiary amine group of LID [<xref rid="B29-pharmaceutics-17-00175" ref-type="bibr">29</xref>]. Furthermore, only a limited degree of proton transfer in co-amorphous FLB-LID systems was observed with increasing LID fractions [<xref rid="B30-pharmaceutics-17-00175" ref-type="bibr">30</xref>], consistent with findings in co-amorphous systems of naproxen and LID [<xref rid="B31-pharmaceutics-17-00175" ref-type="bibr">31</xref>]. In addition, due to the fast crystallization of LID [<xref rid="B32-pharmaceutics-17-00175" ref-type="bibr">32</xref>], it was only possible to obtain anhydrous co-amorphous FLB-LID systems with mole fractions of LID of 0.8 and below. The mole fraction of 0.8 was thus chosen to accommodate two effects. Firstly, to limit the degree of proton transfer, which has been shown to be limited at mole fractions of LID of 0.5 and above. Secondly, to reduce the likelihood for fast recrystallization of LID, observed for mole factions above 0.8. This mole fraction of LID was further used to investigate the effect of water on the co-amorphous FLB-LID system dominated by hydrogen bond formation.</p><p>It has been shown previously that the T<sub>g</sub> of LID linearly increased upon hydration up to a water-to-drug molar ratio of X<sub>H2O</sub> &#x02264; 50%, and the T<sub>g</sub> of hydrated LID remained constant at X<sub>H2O</sub> &#x0003e; 50% [<xref rid="B18-pharmaceutics-17-00175" ref-type="bibr">18</xref>]. The aim of this study was to investigate the effect of water on the stability of the co-amorphous FLB-LID system at X<sub>H2O</sub> &#x02264; 50%. Subsequent analyses on the T<sub>g</sub> of co-amorphous FLB-LID were conducted at three hydration levels of X<sub>H2O</sub> = 0%, 10%, and 50% to investigate if water is an anti-plasticizer for co-amorphous FLB-LID. The crystallization behaviors of anhydrous and hydrated co-amorphous FLB-LID systems were investigated using an isothermal modulated differential scanning calorimetric (iMDSC) method. This technique has been used in previous studies to describe the crystallization process of amorphous materials, particularly polymers [<xref rid="B33-pharmaceutics-17-00175" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceutics-17-00175" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceutics-17-00175" ref-type="bibr">35</xref>], by determining the evolution of heat capacity during crystallization, providing a more accurate calculation of the crystalline fraction compared with the conventional DSC [<xref rid="B36-pharmaceutics-17-00175" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceutics-17-00175" ref-type="bibr">37</xref>]. The time evolution of the crystallization fraction of co-amorphous FLB-LID upon hydration was investigated by the Johnson-Mehl-Avrami (JMA) equation. This model has been widely used to describe the crystallization behavior due to its simplicity and physically meaningful interpretation [<xref rid="B38-pharmaceutics-17-00175" ref-type="bibr">38</xref>]. Furthermore, molecular mobility and thermodynamic factors were investigated to explain the difference in crystallization tendencies of the co-amorphous FLB-LID system upon hydration. The relaxation times of co-amorphous FLB-LID upon hydration were measured by a broadband dielectric spectroscopy (BDS), which has been widely used to determine the time scales of global and local motions related to dipole reorientation in amorphous materials [<xref rid="B39-pharmaceutics-17-00175" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceutics-17-00175" ref-type="bibr">40</xref>]. In addition, the thermodynamics of crystallization were analyzed using configurational thermodynamics.</p></sec><sec id="sec2-pharmaceutics-17-00175"><title>2. Materials and Methods</title><sec id="sec2dot1-pharmaceutics-17-00175"><title>2.1. Materials</title><p>Flurbiprofen (FLB, MW = 244.26 g/mol) was purchased from Cayman Chemical (Ann Arbor, MI, USA). Lidocaine (LID, MW = 234.34 g/mol) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Water (18.2 M&#x003a9;) was freshly prepared using a Milli-Q water system from ELGA LabWater (High Wycombe, UK). The chemical structures of FLB and LID are shown in <xref rid="app1-pharmaceutics-17-00175" ref-type="app">Figure S1</xref>.</p></sec><sec id="sec2dot2-pharmaceutics-17-00175"><title>2.2. Methods</title><sec id="sec2dot2dot1-pharmaceutics-17-00175"><title>2.2.1. Sample Preparation</title><p>Anhydrous and hydrated co-amorphous FLB-LID samples were prepared by melting crystalline mixtures of FLB and LID with a mole fraction of LID of 0.8 (i.e., LID/(FLB + LID)) and water, followed by quench-cooling. The crystalline mixtures of FLB and LID were obtained by gentle mechanical mixing using a plastic pin. Non-hermetically sealed pans were used for the anhydrous samples. For hydrated co-amorphous FLB-LID samples, a droplet of water was added to the anhydrous crystalline mixtures of FLB and LID with a mole fraction of LID of 0.8, followed by water evaporation monitored on a microbalance until the desired total mass was reached. This evaporation process allows precise control of the amount of water to reach the desired total sample mass [<xref rid="B24-pharmaceutics-17-00175" ref-type="bibr">24</xref>]. Hermetically sealed pans were used for the hydrated samples. Our previous study suggests that the T<sub>g</sub> of amorphous LID increased with the addition of water and reached a maximum at a water-to-drug molar ratio (i.e., water/(FLB + LID) &#x000d7; 100%) of X<sub>H2O</sub> = 50% [<xref rid="B18-pharmaceutics-17-00175" ref-type="bibr">18</xref>]. In the current study, water-to-drug molar ratios of X<sub>H2O</sub> = 10% and X<sub>H2O</sub> = 50% were used in hydrated co-amorphous FLB-LID samples. These anhydrous and hydrated co-amorphous samples were subsequently used for thermal and dielectric analyses.</p></sec><sec id="sec2dot2dot2-pharmaceutics-17-00175"><title>2.2.2. X-ray Powder Diffraction (XRPD)</title><p>The solid-state properties of the samples were investigated with an X&#x02019;Pert PRO diffractometer (PANalytical, Almelo, The Netherlands) using Cu K&#x003b1; radiation (&#x003bb; = 1.54187 &#x000c5;) at 45 kV and 40 mA. The samples were measured at room temperature and scanned from 5&#x000b0; to 35&#x000b0; 2&#x003b8; in reflection mode at a scanning speed of 0.067 2&#x003b8;/min and a step size of 0.026&#x000b0; 2&#x003b8;. The XRPD data were analyzed using X&#x02019;Pert HighScore Plus (v2.2.4) software (PANalytical, Almelo, Netherlands).</p></sec><sec id="sec2dot2dot3-pharmaceutics-17-00175"><title>2.2.3. Differential Scanning Calorimetry (DSC)</title><p>The thermal behavior of the co-amorphous samples was measured using a Discovery DSC (TA instruments, New Castle, DE, USA). The instrument was calibrated for temperature using indium and for heat capacity using sapphire discs. Temperature-modulated DSC (MDSC) was conducted under a constant nitrogen flow rate of 50 mL/min. The crystalline mixtures of PRL, LID, and water (total weight about 8 mg) were heated at a rate of 2 K/min with a modulation of 0.212 K every 40 s until above the melting temperature (T<sub>m</sub>). Co-amorphous FLB-LID samples were obtained by cooling the melted drug to 203 K at the maximal instrumental cooling rate. Co-amorphous FLB-LID systems can be made fully amorphous, as indicated by the glass transition events observed during the cooling process. The T<sub>g</sub> was determined by reheating the sample at 2 K/min with a modulation of 0.212 K every 40 s. The reversing heat capacities of the crystalline mixtures (C<sub>p</sub> (crystalline)) and co-amorphous samples (C<sub>p</sub> (amorphous)) were obtained by deconvolution of the total heat capacities. The heat capacity change (&#x00394;C<sub>p</sub>) was obtained by subtraction of the C<sub>p</sub> of the crystalline mixture from the C<sub>p</sub> of the co-amorphous sample at identical temperatures, based on the equation &#x00394;C<sub>p</sub> = C<sub>p</sub> (amorphous&#x02013;C<sub>p</sub> (crystalline) [<xref rid="B11-pharmaceutics-17-00175" ref-type="bibr">11</xref>]. These obtained values of C<sub>p</sub> and &#x00394;C<sub>p</sub> were further used to calculate the crystallization kinetics in subsequent iMDSC measurements of the anhydrous and hydrated co-amorphous FLB-LID systems. The T<sub>g</sub> of the co-amorphous FLB-LID sample was taken at the midpoint of the change in C<sub>p</sub>. The C<sub>p</sub> measurements were conducted using two independent samples.</p><p>The measurements of the T<sub>g</sub>s of anhydrous and hydrated co-amorphous FLB-LID systems were repeated by melting the crystalline mixtures of FLB and LID and crystalline drugs at 10 K/min, followed by cooling the melted drug to 203 K at the maximal instrumental cooling rate. The T<sub>g</sub> was determined by reheating the sample at 2 K/min with a modulation of 0.212 K every 40 s. The T<sub>g</sub> values of anhydrous and hydrated co-amorphous FLB-LID systems with a mole fraction of 0.8 were determined for three independent samples and are reported as mean &#x000b1; standard deviation. The T<sub>g</sub> values of amorphous FLB and co-amorphous FLB-LID systems with mole fractions of LID of 0, 0.1, 0.3, 0.5, and 0.7 were also determined using the same protocol (<italic toggle="yes">n</italic> = 1).</p></sec><sec id="sec2dot2dot4-pharmaceutics-17-00175"><title>2.2.4. Isothermal Crystallization</title><p>The iMDSC measurements were used in this study to calculate the crystallization kinetics from the amorphous forms. This method has been shown to be beneficial in monitoring the crystallization process compared to the conventional DSC measurements [<xref rid="B36-pharmaceutics-17-00175" ref-type="bibr">36</xref>,<xref rid="B41-pharmaceutics-17-00175" ref-type="bibr">41</xref>]. In the iMDSC measurements, the amorphous materials are held at defined temperatures with temperature modulation for extended periods, allowing the measurement of changes in heat capacity during isothermal crystallization as a function of time [<xref rid="B33-pharmaceutics-17-00175" ref-type="bibr">33</xref>]. For very slow crystallization processes, when using a conventional DSC, it is challenging to detect the changes in heat flow during crystallization over extended timescales, rendering it unsuitable for calculating the crystallized fraction [<xref rid="B37-pharmaceutics-17-00175" ref-type="bibr">37</xref>].</p><p>Anhydrous and hydrated co-amorphous FLB-LID samples were prepared in situ by heating the crystalline mixtures at a rate of 10 K/min until melting, then initially equilibrating the sample at 203 K for 2 min, followed by equilibration at three defined temperatures (251 K, 249 K, and 245 K). These temperatures were chosen to investigate the isothermal crystallization behavior of anhydrous and hydrated systems using iMDSC measurements to detect the full crystallization process. Below 245 K, the isothermal crystallization processes of anhydrous and hydrated co-amorphous FLB-LID systems are very slow, and changes in heat capacity during crystallization were hard to detect, as they were confounded with the baseline of the instrument. Above 251 K, the isothermal crystallization is too fast to detect the full crystallization process. Upon isothermal hold, changes in C<sub>p</sub> as a function of time at the defined temperatures (251 K, 249 K, and 245 K) were determined with a modulation of 0.212 K every 40 s [<xref rid="B36-pharmaceutics-17-00175" ref-type="bibr">36</xref>]. The isothermal hold of the co-amorphous samples led to crystallization, resulting in a decrease of C<sub>p</sub>. After the isothermal hold, the co-amorphous samples were equilibrated at 203 K and then reheated to 363 K. This process was conducted to detect potential thermal transitions, including the glass transition of the amorphous components and the melting of crystallized components. These measurements were conducted using two independent samples. The changes in C<sub>p</sub> of anhydrous and hydrated co-amorphous FLB-LID samples upon isothermal hold as a function of time were used to calculate the crystallization fractions (&#x003b1;<sub>cr</sub>):<disp-formula id="FD1-pharmaceutics-17-00175"><label>(1)</label><mml:math id="mm1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="sans-serif">&#x003b1;</mml:mi><mml:mi>cr</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>amorphous</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x000a0;</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mo>&#x000a0;</mml:mo></mml:mrow><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>
where &#x00394;C<sub>p</sub> is the heat capacity change at the defined temperatures (251 K, 249 K, and 245 K) of samples in the amorphous and crystalline forms. C<sub>p</sub> (amorphous) is the C<sub>p</sub> of anhydrous and hydrated co-amorphous FLB-LID systems at the defined temperatures. C<sub>p</sub>(t) is the change of the C<sub>p</sub> upon isothermal hold as a function of time. The values of &#x003b1;<sub>cr</sub> of anhydrous and hydrated co-amorphous FLB-LID samples were assumed independent of the crystalline forms of FLB, LID, and water due to the similarity in C<sub>p</sub> values among the different polymorphs [<xref rid="B9-pharmaceutics-17-00175" ref-type="bibr">9</xref>].</p><p>The Johnson&#x02013;Mehl&#x02013;Avrami (JMA) model was used to describe the crystallization kinetics of anhydrous and hydrated co-amorphous FLB-LID systems, focusing on the combined effect of nucleation and crystal growth. Compared to other models that independently describe nucleation and crystal growth, the JMA model is widely used in pharmaceutical research [<xref rid="B42-pharmaceutics-17-00175" ref-type="bibr">42</xref>]. The JMA model is given as follows [<xref rid="B43-pharmaceutics-17-00175" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceutics-17-00175" ref-type="bibr">44</xref>,<xref rid="B45-pharmaceutics-17-00175" ref-type="bibr">45</xref>]:<disp-formula id="FD2-pharmaceutics-17-00175"><label>(2)</label><mml:math id="mm2" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="sans-serif">&#x003b1;</mml:mi><mml:mi>cr</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mi>exp</mml:mi><mml:mo stretchy="false">[</mml:mo><mml:mo>&#x02212;</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>kt</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mi mathvariant="normal">n</mml:mi></mml:msup></mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>
where t is the crystallization time, and &#x003b1;<sub>cr</sub> is the crystallization fraction. n is the Avrami exponent, describing the nucleation mechanism and growth dimension of crystals. k is the crystallization rate, which is dependent on the rate of nucleation and crystal growth. The JMA fitting was conducted by plotting ln[&#x02212;ln(1 &#x02212; &#x003b1;<sub>cr</sub>)] against ln(t).</p></sec><sec id="sec2dot2dot5-pharmaceutics-17-00175"><title>2.2.5. Broadband Dielectric Spectroscopy (BDS)</title><p>Dielectric measurements of anhydrous and hydrated co-amorphous FLB-LID samples were conducted using an Alpha dielectric spectrometer (Novocontrol GmbH, Montabaur, Germany) over the frequency range from 10<sup>&#x02212;1</sup> to 10<sup>6</sup> Hz. The anhydrous and hydrated crystalline mixtures of FLB, LID, and water (total weight approximately 100 mg) were melted in a preheated oven at 363 K for 2 min. The dielectric measurements of co-amorphous samples were performed immediately after quench-cooling of the melt to 178 K in a parallel-plate cell made of stainless steel (10 mm and 0.1 mm gap provided by silica spacer fibers). The dielectric loss spectra were recorded from 178 K to 250 K with a step size of 5 K from 178 K to 228 K and a step size of 2 K above 228 K. The measurements were conducted using two independent samples.</p></sec><sec id="sec2dot2dot6-pharmaceutics-17-00175"><title>2.2.6. Molecular Mobility</title><p>The dielectric loss spectra were used to determine &#x003b1;-relaxation times (&#x003c4;<sub>&#x003b1;</sub>) of the anhydrous and hydrated co-amorphous systems. The dielectric behaviors of the co-amorphous samples were characterized by the complex relative permittivity, &#x003b5;*(&#x003c9;), across varying frequencies. The Havriliak&#x02013;Negami (HN) function with an additional term describing the DC-conductivity contribution was used to fit the dielectric data [<xref rid="B46-pharmaceutics-17-00175" ref-type="bibr">46</xref>]:<disp-formula id="FD3-pharmaceutics-17-00175"><label>(3)</label><mml:math id="mm3" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">&#x003b5;</mml:mi><mml:mo>*</mml:mo><mml:mo stretchy="false">(</mml:mo></mml:mrow><mml:mi mathvariant="sans-serif">&#x003c9;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="sans-serif">&#x003b5;</mml:mi><mml:mo>&#x0221e;</mml:mo></mml:msub><mml:mo>+</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi><mml:mi mathvariant="sans-serif">&#x003b5;</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo></mml:mrow><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="sans-serif">&#x003c9;</mml:mi><mml:msub><mml:mi mathvariant="sans-serif">&#x003c4;</mml:mi><mml:mi>HN</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mi mathvariant="sans-serif">&#x003b1;</mml:mi></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mi mathvariant="sans-serif">&#x003b2;</mml:mi></mml:msup></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>+</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mi mathvariant="sans-serif">&#x003c3;</mml:mi><mml:mi>dc</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="sans-serif">&#x003b5;</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="sans-serif">&#x003c9;</mml:mi></mml:mrow></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:math></disp-formula>
where &#x003b5;<sub>&#x0221e;</sub> is the high-frequency limit permittivity, &#x003b5;<sub>0</sub> is the free space permittivity, and &#x003c3;<sub>dc</sub> is the DC-conductivity. &#x00394;&#x003b5; is the dielectric strength, &#x003c9; is equal to 2&#x003c0;f, &#x003c4;<sub>HN</sub> is the HN relaxation time, and &#x003b1; and &#x003b2; represent the symmetric and asymmetric broadening of the relaxation peak. From the fitting parameters in Equation (3), the values of &#x003c4;<sub>&#x003b1;</sub> of anhydrous and hydrated co-amorphous FLB-LID systems were obtained from Equation (4):<disp-formula id="FD4-pharmaceutics-17-00175"><label>(4)</label><mml:math id="mm4" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="sans-serif">&#x003c4;</mml:mi><mml:mi mathvariant="sans-serif">&#x003b1;</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="sans-serif">&#x003c4;</mml:mi><mml:mi>HN</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>sin</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mi mathvariant="sans-serif">&#x003c0;</mml:mi><mml:mi mathvariant="sans-serif">&#x003b1;</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi mathvariant="sans-serif">&#x003b2;</mml:mi></mml:mrow></mml:mrow></mml:mfrac></mml:mstyle><mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mi mathvariant="sans-serif">&#x003b1;</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mi mathvariant="sans-serif">&#x003c0;</mml:mi><mml:mi mathvariant="sans-serif">&#x003b1;</mml:mi><mml:mi mathvariant="sans-serif">&#x003b2;</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi mathvariant="sans-serif">&#x003b2;</mml:mi></mml:mrow></mml:mrow></mml:mfrac></mml:mstyle><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mi mathvariant="sans-serif">&#x003b1;</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>The temperature evolutions of the &#x003b1;-relaxation times (&#x003c4;<sub>&#x003b1;</sub>(T)) of anhydrous and hydrated co-amorphous FLB-LID systems were further fitted with the Vogel&#x02013;Fulcher&#x02013;Tammann (VFT) equation [<xref rid="B47-pharmaceutics-17-00175" ref-type="bibr">47</xref>]:<disp-formula id="FD5-pharmaceutics-17-00175"><label>(5)</label><mml:math id="mm5" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="sans-serif">&#x003c4;</mml:mi><mml:mi mathvariant="sans-serif">&#x003b1;</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">T</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="sans-serif">&#x003c4;</mml:mi><mml:mo>&#x0221e;</mml:mo></mml:msub><mml:mrow><mml:mi>exp</mml:mi><mml:mo stretchy="false">[</mml:mo></mml:mrow><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mi>DT</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">T</mml:mi><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi mathvariant="normal">T</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>
where &#x003c4;<sub>&#x0221e;</sub>, T<sub>0</sub>, and D are fitting parameters. &#x003c4;<sub>&#x0221e;</sub> is the relaxation time of unrestricted material, which should be in the order of around 10<sup>&#x02212;14</sup> s (i.e., vibrational frequency of molecules). T<sub>0</sub> is the zero-mobility temperature, and D is the strength parameter.</p></sec></sec></sec><sec sec-type="results" id="sec3-pharmaceutics-17-00175"><title>3. Results and Discussions</title><sec id="sec3dot1-pharmaceutics-17-00175"><title>3.1. T<sub>g</sub>s of Anhydrous and Hydrated Co-Amorphous FLB-LID Systems</title><p>As a first step, the establishment of co-amorphous systems with varying FLB-LID ratios was confirmed by XRPD (<xref rid="pharmaceutics-17-00175-f001" ref-type="fig">Figure 1</xref>). It can be seen that anhydrous co-amorphous FLB-LID with mole fractions of LID from 0.2 to 0.8 can be made amorphous at room temperature. Although these ambient temperature measurements cannot be directly correlated with the later DSC and BDS experiments, which were conducted at very low temperatures, the formation of co-amorphous systems was confirmed.</p><p>In the following, the influence of water on the T<sub>g</sub> of co-amorphous FLB-LID systems was investigated. The experimental T<sub>g</sub>s of anhydrous and hydrated pure amorphous FLB and co-amorphous FLB-LID systems with mole fractions of LID of 0, 0.1, 0.3, 0.5, 0.7, and 0.8 are shown in <xref rid="app1-pharmaceutics-17-00175" ref-type="app">Table S1</xref>. The changes in the experimental T<sub>g</sub>s of co-amorphous FLB-LID systems with high mole fractions of LID (0.7 and 0.8) upon hydration were lower than those with low mole fractions, indicating that the plasticizing effect of water on co-amorphous FLB-LID systems is more pronounced at lower mole fractions of LID.</p><p>The experimental T<sub>g</sub> of the anhydrous co-amorphous FLB-LID system with a mole fraction of LID of 0.8 was found to be 228.6 &#x000b1; 0.2 K. The experimental T<sub>g</sub>s of hydrated co-amorphous FLB-LID systems with water-to-drug molar ratios of X<sub>H2O</sub> = 10% and X<sub>H2O</sub> = 50% were found to be 227.8 &#x000b1; 0.2 K, and 227.1 &#x000b1; 1.0 K, respectively. The experimental T<sub>g</sub> of the hydrated co-amorphous FLB-LID system with X<sub>H2O</sub> = 10% exhibited a minimal reduction of 0.8 &#x000b1; 0.2 K, compared with the T<sub>g</sub> of the anhydrous system. Furthermore, there is no significant difference between the T<sub>g</sub>s of the anhydrous co-amorphous FLB-LID system and hydrated co-amorphous FLB-LID system with X<sub>H2O</sub> = 50% (Student&#x02019;s <italic toggle="yes">t</italic>-test, <italic toggle="yes">p</italic> &#x0003c; 0.05). Thus, it has been shown that the addition of water of X<sub>H2O</sub> = 10% and X<sub>H2O</sub> = 50% showed a minimal impact on the experimental T<sub>g</sub> of the co-amorphous FLB-LID system with a mole fraction of LID of 0.8.</p><p>The effect of water on the T<sub>g</sub> of the co-amorphous FLB-LID system was further fitted using the extended version of the Fox equation [<xref rid="B48-pharmaceutics-17-00175" ref-type="bibr">48</xref>]:<disp-formula id="FD6-pharmaceutics-17-00175"><label>(6)</label><mml:math id="mm6" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="normal">T</mml:mi><mml:mrow><mml:mi mathvariant="normal">g</mml:mi><mml:mn>123</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mi mathvariant="normal">w</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="normal">T</mml:mi><mml:mrow><mml:mi mathvariant="normal">g</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>+</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mi mathvariant="normal">w</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="normal">T</mml:mi><mml:mrow><mml:mi mathvariant="normal">g</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>+</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mi mathvariant="normal">w</mml:mi><mml:mn>3</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="normal">T</mml:mi><mml:mrow><mml:mi mathvariant="normal">g</mml:mi><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:math></disp-formula>
where T<sub>g123</sub> is the theoretical T<sub>g</sub> of anhydrous and hydrated co-amorphous FLB-LID systems, respectively. T<sub>g1</sub>, T<sub>g2</sub>, T<sub>g3</sub>, w<sub>1</sub>, w<sub>2</sub>, and w<sub>3</sub> are the T<sub>g</sub>s and weight fractions of the individual components, respectively. For the first approach, considering water as a pure plasticizer, FLB (T<sub>g1</sub> = 268.0 K), LID (T<sub>g2</sub> = 209.8 K), and water (T<sub>g3</sub> = 136.0 K) were treated as three individual components in Equation (6). Consequently, the theoretical T<sub>g</sub> of the co-amorphous FLB-LID system was expected to decrease by 1.0 K with X<sub>H2O</sub> = 10% and by 4.9 K with X<sub>H2O</sub> = 50%, respectively. Inconsistencies were thus noted between the observed changes in the theoretical T<sub>g</sub> of the co-amorphous FLB-LID system upon hydration and the experimental T<sub>g</sub>. In the second approach, water was considered a plasticizer for FLB and an anti-plasticizer for LID. It was assumed that water was distributed molecularly evenly between FLB and LID. The theoretical T<sub>g</sub> of hydrated FLB, influenced by water as a plasticizer, was regarded as an individual component in Equation (6) (T<sub>g1</sub> = 266.1 K for X<sub>H2O</sub> = 10%, and 259.1 K for X<sub>H2O</sub> = 50%). It has been previously reported that the T<sub>g</sub> of hydrated LID exhibits a linear increase with the addition of water, reaching a maximum at X<sub>H2O</sub> = 50% with an increase of 0.9 K (T<sub>g2</sub> = 210.0 K for X<sub>H2O</sub> = 10% and 210.9 K for X<sub>H2O</sub> = 50%) [<xref rid="B18-pharmaceutics-17-00175" ref-type="bibr">18</xref>]. Based on the second approach, the addition of water resulted in minimal changes in the theoretical T<sub>g</sub> of the co-amorphous FLB-LID system, decreasing by 0.1 K for X<sub>H2O</sub> = 10% and increasing by 0.4 K for X<sub>H2O</sub> = 50%. Thus, the second approach leads to a better fit with the observed changes in the experimental T<sub>g</sub> of the co-amorphous FLB-LID system upon hydration, compared with the first approach. Therefore, the minimal changes of the T<sub>g</sub> of the co-amorphous FLB-LID system upon hydration are attributed to the dual effects of water, i.e., its plasticizing effect on FLB and its anti-plasticizing effect on LID.</p></sec><sec id="sec3dot2-pharmaceutics-17-00175"><title>3.2. Isothermal Crystallization</title><sec id="sec3dot2dot1-pharmaceutics-17-00175"><title>3.2.1. Kinetics of Crystallization</title><p>The crystallization behavior of anhydrous and hydrated co-amorphous FLB-LID systems with a mole fraction of LID of 0.8 was investigated upon isothermal hold at three defined temperatures (245 K, 249 K, and 251 K). This temperature range above the T<sub>g</sub> was chosen because the co-amorphous FLB-LID system exhibited a relatively high crystallization tendency compared to the behavior below the T<sub>g</sub> [<xref rid="B10-pharmaceutics-17-00175" ref-type="bibr">10</xref>]. XRPD on anhydrous and hydrated co-amorphous FLB-LID systems after isothermal partial crystallization showed reflections corresponding to LID at various water ratios, indicating that the crystallized component during isothermal crystallization mainly consisted of crystallized LID (<xref rid="pharmaceutics-17-00175-f002" ref-type="fig">Figure 2</xref>).</p><p>The total heat flow of anhydrous and hydrated co-amorphous FLB-LID systems as a function of time, determined through the iMDSC measurements, is shown in <xref rid="app1-pharmaceutics-17-00175" ref-type="app">Figure S2</xref>. Furthermore, the crystallization fraction of the co-amorphous FLB-LID system was calculated based on Equation (1). The anhydrous and hydrated co-amorphous FLB-LID systems began to crystallize at the onset of the isothermal hold at various temperatures (<xref rid="pharmaceutics-17-00175-f003" ref-type="fig">Figure 3</xref>). This fast crystallization might be attributed to the high concentration of LID within the co-amorphous FLB-LID system since the amorphous form of LID does not remain stable alone and crystallizes immediately [<xref rid="B32-pharmaceutics-17-00175" ref-type="bibr">32</xref>]. Furthermore, the crystallization fractions and crystallization complete-time of anhydrous and hydrated co-amorphous FLB-LID systems at the defined temperatures are shown in <xref rid="pharmaceutics-17-00175-t001" ref-type="table">Table 1</xref>. The crystallization fractions of the co-amorphous FLB-LID system at the various temperatures remained consistent, showing average crystallization fractions of 66.0 &#x000b1; 2.5% for X<sub>H2O</sub> = 0%, 60.9 &#x000b1; 1.2% for X<sub>H2O</sub> = 10%, and 32.6 &#x000b1; 5.1% for X<sub>H2O</sub> = 50%. The crystallization complete-time of anhydrous and hydrated co-amorphous FLB-LID systems decreased with the increasing temperatures. In contrast, at a constant temperature, the crystallization complete time of the co-amorphous FLB-LID system was increased upon hydration.</p><p>The JMA model was used to fit the crystallization fractions of anhydrous and hydrated co-amorphous FLB-LID systems, using Equation (2). The JMA model is based on the assumption that the growth of crystals occurs at a constant velocity [<xref rid="B42-pharmaceutics-17-00175" ref-type="bibr">42</xref>]. It is assumed that only a single solid phase participates in the isothermal crystallization of anhydrous and hydrated systems, as indicated by a single melting endotherm attributed to the crystallized component, as shown in <xref rid="pharmaceutics-17-00175-f004" ref-type="fig">Figure 4</xref>. A detailed discussion follows in <xref rid="sec3dot2dot2-pharmaceutics-17-00175" ref-type="sec">Section 3.2.2</xref>. For anhydrous and hydrated co-amorphous FLB-LID systems, the JMA model could be fitted to the isothermal crystallization process during the initial and middle stages of crystallization (<xref rid="pharmaceutics-17-00175-f003" ref-type="fig">Figure 3</xref>, black dashed lines). The JMA fitting parameters are shown in <xref rid="pharmaceutics-17-00175-t001" ref-type="table">Table 1</xref>. However, in the final stages of crystallization of anhydrous and hydrated co-amorphous FLB-LID systems, the JMA model failed to fit the data. One possible reason could be related to the rapid growth of crystals occurring at the final stages of crystallization, which has been observed in other amorphous drugs and systems [<xref rid="B49-pharmaceutics-17-00175" ref-type="bibr">49</xref>,<xref rid="B50-pharmaceutics-17-00175" ref-type="bibr">50</xref>,<xref rid="B51-pharmaceutics-17-00175" ref-type="bibr">51</xref>]. The Avrami exponent (n) of anhydrous and hydrated co-amorphous FLB-LID systems during isothermal crystallization was between 1.5 and 2.5, indicating small nucleation dimensions for the anhydrous and hydrated systems. The range of the n values of the co-amorphous FLB-LID system was consistent with the n values observed in a co-amorphous system of lurasidone hydrochloride and saccharin [<xref rid="B10-pharmaceutics-17-00175" ref-type="bibr">10</xref>]. Compared with the anhydrous co-amorphous FLB-LID system, the values for the crystallization rate (k) of the co-amorphous FLB-LID system decreased upon hydration. This indicates that water decreased the rates of nucleation and crystal growth during isothermal crystallization.</p><p>Overall, considering the crystallization fractions, crystallization complete-time, and crystallization rates of anhydrous and hydrated co-amorphous FLB-LID systems, the crystallization tendency of the co-amorphous FLB-LID system was decreased upon hydration.</p></sec><sec id="sec3dot2dot2-pharmaceutics-17-00175"><title>3.2.2. Form of Water</title><p>The observed minimal changes in the T<sub>g</sub>s of co-amorphous FLB-LID systems upon hydration (<xref rid="sec3dot1-pharmaceutics-17-00175" ref-type="sec">Section 3.1</xref>) indicated that water interacted with both FLB and LID, with water showing an anti-plasticizing effect on LID and a plasticizing effect on FLB. Water in an amorphous matrix can be classified into three forms based on its thermodynamic properties: non-freezable water, freezable bound water, and free water [<xref rid="B52-pharmaceutics-17-00175" ref-type="bibr">52</xref>]. Non-freezable water is closely bound to the amorphous matrix and does not exhibit a phase transition during calorimetric analysis. Freezable-bound water is less tightly bound to the matrix and shows melting and crystallization temperatures that are different from those of bulk water, whilst free water exhibits the thermodynamic properties of bulk water.</p><p>DSC was conducted to compare the thermal transitions between the anhydrous and hydrated systems after isothermal crystallization. After isothermal (partial) crystallization at 245 K, 249 K, and 251 K (<xref rid="pharmaceutics-17-00175-f004" ref-type="fig">Figure 4</xref>), all anhydrous co-amorphous FLB-LID systems showed a glass transition at 263.1 K. In a similar manner, at X<sub>H2O</sub> = 10%, a T<sub>g</sub> of 256.7 K was found for all three isothermal conditions, whilst at X<sub>H2O</sub> = 50%, a T<sub>g</sub> of 246.9 K was found for all three conditions. This consistency aligns with the similar crystallization fractions found at various temperatures, as shown in <xref rid="pharmaceutics-17-00175-t001" ref-type="table">Table 1</xref>. The T<sub>g</sub> at 263.1 K for the anhydrous co-amorphous FLB-LID system is closer to the T<sub>g</sub> of pure FLB (268.0 K) than to the T<sub>g</sub> of pure LID (209.8 K) (<xref rid="pharmaceutics-17-00175-f004" ref-type="fig">Figure 4</xref>A). This indicates that the remaining amorphous component mainly consisted of amorphous FLB and only a small fraction of amorphous LID. In addition, a single endothermic transition was observed at 313.1 K, attributed to the melting of the crystallized component. This T<sub>m</sub> is closer to the T<sub>m</sub> of LID (341.6 K) compared to the T<sub>m</sub> of FLB (390.2 K), indicating that the crystallized component of the anhydrous system during isothermal crystallization mainly consisted of crystallized LID.</p><p>For hydrated co-amorphous systems with X<sub>H2O</sub> = 10% and 50%, the T<sub>g</sub> and T<sub>m</sub> were lower than the anhydrous system, as shown in <xref rid="pharmaceutics-17-00175-f004" ref-type="fig">Figure 4</xref>. The decreased T<sub>g</sub>s of the hydrated co-amorphous FLB-LID systems could be attributed to the plasticizing effect of water on the remaining amorphous component since it mainly consists of amorphous FLB. In addition, the observed decrease in the T<sub>m</sub> of the crystallized component for the hydrated co-amorphous FLB-LID system can be attributed to the effect of water on the crystallized solids [<xref rid="B53-pharmaceutics-17-00175" ref-type="bibr">53</xref>].</p><p>No additional thermal transitions that could be attributed to water were observed for the hydrated systems compared with the anhydrous system. This observation indicates that the form of water existing in the hydrated co-amorphous FLB-LID system can be attributed to non-freezable water. This result is consistent with our previous findings that the anti-plasticizing effect of water on LID is due to a specific hydrogen bonding pattern between water and the carbonyl group of LID [<xref rid="B22-pharmaceutics-17-00175" ref-type="bibr">22</xref>]. Overall, the thermograms of anhydrous and hydrated co-amorphous FLB-LID systems upon isothermal crystallization show that water closely interacts with the co-amorphous FLB-LID system, thus affecting the crystallization process of both FLB and LID within the system.</p></sec></sec><sec id="sec3dot3-pharmaceutics-17-00175"><title>3.3. Molecular Mobility</title><p>For amorphous drugs and systems, isothermal hold above T<sub>g</sub> can facilitate the crystallization process, attributed to the increased &#x003b1;-relaxation compared with the conditions below T<sub>g</sub> [<xref rid="B54-pharmaceutics-17-00175" ref-type="bibr">54</xref>]. <xref rid="app1-pharmaceutics-17-00175" ref-type="app">Figure S3</xref> shows the dielectric loss spectra of anhydrous and hydrated co-amorphous FLB-LID systems. As shown in <xref rid="pharmaceutics-17-00175-f003" ref-type="fig">Figure 3</xref>, the &#x003b1;-relaxation times of anhydrous and hydrated co-amorphous FLB-LID systems exhibited similar temperature dependences. The VFT fit (Equation (5)) was used to describe the temperature evolution of the &#x003b1;-relaxation times of anhydrous and hydrated co-amorphous FLB-LID systems (<xref rid="pharmaceutics-17-00175-f005" ref-type="fig">Figure 5</xref>, dashed lines). The VFT fitting parameters are shown in <xref rid="app1-pharmaceutics-17-00175" ref-type="app">Table S2</xref>. The T<sub>g</sub>s, as determined by the VFT fit, were recognized at the point where &#x003c4;<sub>&#x003b1;</sub> reached 100 s. The T<sub>g</sub>s of anhydrous and hydrated co-amorphous FLB-LID systems were found to be 226.4 K for X<sub>H2O</sub> = 0%, 226.5 K for X<sub>H2O</sub> = 10%, and 227.3 K for X<sub>H2O</sub> = 50%, in agreement with the T<sub>g</sub>s obtained from the DSC measurements. It has been shown that as the temperature increases, the molecular mobility of anhydrous and hydrated co-amorphous FLB-LID systems increases, as indicated by reduced &#x003b1;-relaxation times (&#x003c4;<sub>&#x003b1;</sub>), corresponding to an increased crystallization complete-time. However, anhydrous and hydrated co-amorphous FLB-LID systems exhibited similar mobility at constant temperatures. Overall, it can be stated that molecular mobility alone cannot explain the isothermal crystallization behavior of the co-amorphous FLB-LID system during hydration.</p></sec><sec id="sec3dot4-pharmaceutics-17-00175"><title>3.4. Configurational Thermodynamics</title><p>In addition to molecular mobility, it has been previously demonstrated that configurational thermodynamics, particularly the differences in entropy and Gibbs free energy between the amorphous and crystalline phases, could influence the physical stability of amorphous drugs and systems [<xref rid="B10-pharmaceutics-17-00175" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-17-00175" ref-type="bibr">11</xref>]. Previous research has recognized that the difference in Gibbs free energy (&#x00394;G) between the amorphous and crystalline phases is the thermodynamic driving force for crystallization [<xref rid="B55-pharmaceutics-17-00175" ref-type="bibr">55</xref>,<xref rid="B56-pharmaceutics-17-00175" ref-type="bibr">56</xref>]. However, in the case of over ten amorphous compounds, a greater entropy difference (&#x00394;S) between the amorphous and crystalline phases indicated enhanced stability, regardless of the thermodynamic driving force involved [<xref rid="B5-pharmaceutics-17-00175" ref-type="bibr">5</xref>,<xref rid="B11-pharmaceutics-17-00175" ref-type="bibr">11</xref>]. Furthermore, for amorphous nifedipine, indomethacin, felodipine, and ketoconazole, the difference in crystallization propensity was explained in terms of the difference in the thermodynamic activation barrier, which correlated to the empirical relation ((T&#x00394;S)<sup>3</sup>/&#x00394;G<sup>2</sup>) [<xref rid="B9-pharmaceutics-17-00175" ref-type="bibr">9</xref>].</p><p>The &#x00394;G of anhydrous and hydrated co-amorphous FLB-LID systems at a temperature (T) is related to the configurational enthalpy (&#x00394;H) and entropy (&#x00394;S) as shown in Equation (7):<disp-formula id="FD7-pharmaceutics-17-00175"><label>(7)</label><mml:math id="mm7" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi><mml:mi mathvariant="normal">G</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi><mml:mi mathvariant="normal">H</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi mathvariant="normal">T</mml:mi><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi><mml:mi mathvariant="normal">S</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>The difference in C<sub>p</sub>s as a function of temperature (&#x00394;C<sub>p</sub>(T)) between the amorphous and crystalline phases of the co-amorphous FLB-LID systems, as shown in <xref rid="app1-pharmaceutics-17-00175" ref-type="app">Figure S4</xref>, was used to obtain the values of &#x00394;H and &#x00394;S, according to the following equations:<disp-formula id="FD8-pharmaceutics-17-00175"><label>(8)</label><mml:math id="mm8" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi><mml:mi mathvariant="normal">H</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi><mml:msub><mml:mi mathvariant="normal">H</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:msubsup><mml:mo stretchy="false">&#x0222b;</mml:mo><mml:mrow><mml:mi mathvariant="normal">T</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">T</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">T</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="FD9-pharmaceutics-17-00175"><label>(9)</label><mml:math id="mm9" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi><mml:mi mathvariant="normal">S</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi><mml:msub><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:msubsup><mml:mo stretchy="false">&#x0222b;</mml:mo><mml:mrow><mml:mi mathvariant="normal">T</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">T</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow></mml:mfrac></mml:mstyle><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">T</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula>
where &#x00394;H<sub>m</sub> and &#x00394;S<sub>m</sub> are the enthalpy and entropy of fusion for the fully crystallized component from the co-amorphous FLB-LID system, calculated by:<disp-formula id="FD10-pharmaceutics-17-00175"><label>(10)</label><mml:math id="mm10" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi><mml:msub><mml:mi mathvariant="normal">H</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:msub></mml:mrow><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi><mml:msub><mml:mi mathvariant="normal">H</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>cr</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="sans-serif">&#x003b1;</mml:mi><mml:mi>cr</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="FD11-pharmaceutics-17-00175"><label>(11)</label><mml:math id="mm11" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi><mml:msub><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:msub></mml:mrow><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mi mathvariant="sans-serif">&#x00394;</mml:mi><mml:msub><mml:mi mathvariant="normal">H</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="normal">T</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:math></disp-formula>
where T<sub>m</sub> and &#x00394;H<sub>m</sub>(cr) are the melting temperature and enthalpy of the crystalline component following isothermal crystallization, as determined by a DSC (<xref rid="pharmaceutics-17-00175-f004" ref-type="fig">Figure 4</xref>). &#x003b1;<sub>cr</sub> is the average crystallization fraction of anhydrous and hydrated co-amorphous FLB-LID systems.</p><p>The calculated values for &#x00394;G, &#x00394;S, and (T&#x00394;S)<sup>3</sup>/&#x00394;G<sup>2</sup> of anhydrous and hydrated co-amorphous FLB-LID systems are shown in <xref rid="pharmaceutics-17-00175-f006" ref-type="fig">Figure 6</xref>. To compare the anhydrous and hydrated co-amorphous FLB-LID systems, which exhibited similar glass transitions but different melting points, the temperature scale was normalized using a reduced temperature, i.e., (T &#x02013; T<sub>g</sub>)/(T<sub>m</sub> &#x02013; T<sub>g</sub>). The values of &#x00394;G of anhydrous and hydrated co-amorphous FLB-LID systems decreased with increasing temperature, approaching zero at the melting point, consistent with previous findings [<xref rid="B9-pharmaceutics-17-00175" ref-type="bibr">9</xref>,<xref rid="B11-pharmaceutics-17-00175" ref-type="bibr">11</xref>]. Over the temperature range, the values of &#x00394;G of anhydrous and hydrated co-amorphous FLB-LID systems were ranked as X<sub>H2O</sub> = 50% &#x0003e; X<sub>H2O</sub> = 0% &#x0003e; X<sub>H2O</sub> = 10%. The higher value of &#x00394;G indicates that the hydrated co-amorphous FLB-LID system with X<sub>H2O</sub> = 50% exhibited a higher thermodynamic driving force towards crystallization compared with the other systems. This finding is in contrast to the decreased crystallization tendency of the co-amorphous FLB-LID system upon hydration, indicating that their crystallization tendencies cannot be explained solely by the value of &#x00394;G. It was found that over most of the temperature range, the values of &#x00394;S and (T&#x00394;S)<sup>3</sup>/&#x00394;G<sup>2</sup> of anhydrous and hydrated co-amorphous FLB-LID systems could be ranked as X<sub>H2O</sub> = 50% &#x0003e; X<sub>H2O</sub> = 10% &#x02248; X<sub>H2O</sub> = 0%, which was consistent with the actual crystallization tendencies of these systems. Overall, the configurational thermodynamic analysis indicated that the decreased crystallization tendency of the hydrated co-amorphous FLB-LID system could be associated with the larger entropic (&#x00394;S) and thermodynamic activation barriers ((T&#x00394;S)<sup>3</sup>/&#x00394;G<sup>2</sup>) upon hydration.</p></sec></sec><sec sec-type="conclusions" id="sec4-pharmaceutics-17-00175"><title>4. Conclusions</title><p>In this study, the effect of LID as a co-former on the stability of the co-amorphous FLB-LID system, with a mole fraction of LID of 0.8 upon hydration, was investigated. In the co-amorphous FLB-LID system, water acted as a plasticizer for FLB, while it exhibited an anti-plasticizing effect on LID. The crystallization tendency of the co-amorphous FLB-LID system decreased with the addition of water. It was found that molecular mobility was not a dominating factor in stabilizing the co-amorphous FLB-LID system upon hydration. Rather, from the thermodynamic measurements, it was found that the hydrated co-amorphous FLB-LID system exhibited higher values for &#x00394;S and (T&#x00394;S)<sup>3</sup>/&#x00394;G<sup>2</sup>, compared with the anhydrous system. Therefore, the decrease in crystallization tendency of the co-amorphous FLB-LID system upon hydration was associated with higher entropic and thermodynamic activation barriers towards crystallization.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmaceutics-17-00175"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/pharmaceutics17020175/s1">https://www.mdpi.com/article/10.3390/pharmaceutics17020175/s1</uri>, Table S1: Experimental T<sub>g</sub>s (<italic toggle="yes">n</italic> = 1) of anhydrous and hydrated pure amorphous FLB and co-amorphous FLB-LID systems with mole fractions of LID of 0, 0.1, 0.3, 0.5, 0.7 0.8; Table S2: VFT fitting parameters of anhydrous and hydrated co-amorphous FLB-LID systems with water-to-drug molar ratios of X<sub>H2O</sub> = 0%, X<sub>H2O</sub> = 10%, and X<sub>H2O</sub> = 50%; Figure S1: Chemical structures of FLB and LID; Figure S2: Total heat flow of anhydrous and hydrated co-amorphous FLB-LID systems with water-to-drug molar ratios of X<sub>H2O</sub> = 0%, X<sub>H2O</sub> = 10%, and X<sub>H2O</sub> = 50% at 251 K, 249 K, and 245 K from iMDSC measurements; Figure S3: Dielectric loss spectra collected above the T<sub>g</sub>s of anhydrous and hydrated co-amorphous FLB-LID systems with water-to-drug molar ratios of X<sub>H2O</sub> = 0%, X<sub>H2O</sub> = 10%, and X<sub>H2O</sub> = 50%; Figure S4: Difference in C<sub>p</sub>s as a function of temperature (&#x00394;C<sub>p</sub>(T)) between the amorphous and crystalline phases of the anhydrous and hydrated co-amorphous FLB-LID systems with water-to-drug molar ratios of X<sub>H2O</sub> = 0%, X<sub>H2O</sub> = 10%, and X<sub>H2O</sub> = 50%.</p><supplementary-material id="pharmaceutics-17-00175-s001" position="float" content-type="local-data"><media xlink:href="pharmaceutics-17-00175-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, X.X., H.G., J.K.-K., M.P. and T.R.; methodology, X.X., H.G., J.K.-K., M.P. and T.R.; formal analysis, X.X. and J.K.-K.; investigation, X.X. and J.K.-K.; resources, H.G., J.K.-K., M.P. and T.R.; writing&#x02014;original draft preparation, X.X.; writing&#x02014;review and editing, X.X., H.G., J.K.-K., M.P. and T.R.; visualization, X.X.; supervision, H.G. and T.R.; project administration, H.G. and T.R. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available on request from the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-17-00175"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hancock</surname><given-names>B.C.</given-names></name>
<name><surname>Zografi</surname><given-names>G.</given-names></name>
</person-group><article-title>Characteristics and significance of the amorphous state in pharmaceutical systems</article-title><source>J. Pharm. Sci.</source><year>1997</year><volume>86</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1021/js9601896</pub-id><pub-id pub-id-type="pmid">9002452</pub-id>
</element-citation></ref><ref id="B2-pharmaceutics-17-00175"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kasten</surname><given-names>G.</given-names></name>
<name><surname>L&#x000f6;bmann</surname><given-names>K.</given-names></name>
<name><surname>Grohganz</surname><given-names>H.</given-names></name>
<name><surname>Rades</surname><given-names>T.</given-names></name>
</person-group><article-title>Co-former selection for co-amorphous drug-amino acid formulations</article-title><source>Int. J. Pharm.</source><year>2019</year><volume>557</volume><fpage>366</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2018.12.036</pub-id><pub-id pub-id-type="pmid">30578980</pub-id>
</element-citation></ref><ref id="B3-pharmaceutics-17-00175"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dengale</surname><given-names>S.J.</given-names></name>
<name><surname>Grohganz</surname><given-names>H.</given-names></name>
<name><surname>Rades</surname><given-names>T.</given-names></name>
<name><surname>L&#x000f6;bmann</surname><given-names>K.</given-names></name>
</person-group><article-title>Recent advances in co-amorphous drug formulations</article-title><source>Adv. Drug Deliv. Rev.</source><year>2016</year><volume>100</volume><fpage>116</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2015.12.009</pub-id><pub-id pub-id-type="pmid">26805787</pub-id>
</element-citation></ref><ref id="B4-pharmaceutics-17-00175"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>L&#x000f6;bmann</surname><given-names>K.</given-names></name>
<name><surname>Laitinen</surname><given-names>R.</given-names></name>
<name><surname>Grohganz</surname><given-names>H.</given-names></name>
<name><surname>Gordon</surname><given-names>K.C.</given-names></name>
<name><surname>Strachan</surname><given-names>C.</given-names></name>
<name><surname>Rades</surname><given-names>T.</given-names></name>
</person-group><article-title>Coamorphous drug systems: Enhanced physical stability and dissolution rate of indomethacin and naproxen</article-title><source>Mol. Pharm.</source><year>2011</year><volume>8</volume><fpage>1919</fpage><lpage>1928</lpage><pub-id pub-id-type="doi">10.1021/mp2002973</pub-id><pub-id pub-id-type="pmid">21815614</pub-id>
</element-citation></ref><ref id="B5-pharmaceutics-17-00175"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>D.</given-names></name>
<name><surname>Zhang</surname><given-names>G.G.</given-names></name>
<name><surname>Law</surname><given-names>D.</given-names></name>
<name><surname>Grant</surname><given-names>D.J.</given-names></name>
<name><surname>Schmitt</surname><given-names>E.A.</given-names></name>
</person-group><article-title>Physical stability of amorphous pharmaceuticals: Importance of configurational thermodynamic quantities and molecular mobility</article-title><source>J. Pharm. Sci.</source><year>2002</year><volume>91</volume><fpage>1863</fpage><lpage>1872</lpage><pub-id pub-id-type="doi">10.1002/jps.10169</pub-id><pub-id pub-id-type="pmid">12115813</pub-id>
</element-citation></ref><ref id="B6-pharmaceutics-17-00175"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>P.</given-names></name>
<name><surname>Chawla</surname><given-names>G.</given-names></name>
<name><surname>Bansal</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Physical stability and solubility advantage from amorphous celecoxib: The role of thermodynamic quantities and molecular mobility</article-title><source>Mol. Pharm.</source><year>2004</year><volume>1</volume><fpage>406</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1021/mp049938f</pub-id><pub-id pub-id-type="pmid">16028352</pub-id>
</element-citation></ref><ref id="B7-pharmaceutics-17-00175"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mehta</surname><given-names>M.</given-names></name>
<name><surname>Ragoonanan</surname><given-names>V.</given-names></name>
<name><surname>McKenna</surname><given-names>G.B.</given-names></name>
<name><surname>Suryanarayanan</surname><given-names>R.</given-names></name>
</person-group><article-title>Correlation between Molecular Mobility and Physical Stability in Pharmaceutical Glasses</article-title><source>Mol. Pharm.</source><year>2016</year><volume>13</volume><fpage>1267</fpage><lpage>1277</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.5b00853</pub-id><pub-id pub-id-type="pmid">26895136</pub-id>
</element-citation></ref><ref id="B8-pharmaceutics-17-00175"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kissi</surname><given-names>E.O.</given-names></name>
<name><surname>Grohganz</surname><given-names>H.</given-names></name>
<name><surname>L&#x000f6;bmann</surname><given-names>K.</given-names></name>
<name><surname>Ruggiero</surname><given-names>M.T.</given-names></name>
<name><surname>Zeitler</surname><given-names>J.A.</given-names></name>
<name><surname>Rades</surname><given-names>T.</given-names></name>
</person-group><article-title>Glass-transition temperature of the &#x003b2;-Relaxation as the major predictive parameter for recrystallization of neat amorphous drugs</article-title><source>J. Phys. Chem. B</source><year>2018</year><volume>122</volume><fpage>2803</fpage><lpage>2808</lpage><pub-id pub-id-type="doi">10.1021/acs.jpcb.7b10105</pub-id><pub-id pub-id-type="pmid">29498523</pub-id>
</element-citation></ref><ref id="B9-pharmaceutics-17-00175"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Krishna Kumar</surname><given-names>N.S.</given-names></name>
<name><surname>Suryanarayanan</surname><given-names>R.</given-names></name>
</person-group><article-title>Crystallization propensity of amorphous pharmaceuticals: Kinetics and thermodynamics</article-title><source>Mol. Pharm.</source><year>2022</year><volume>19</volume><fpage>472</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.1c00839</pub-id><pub-id pub-id-type="pmid">34979803</pub-id>
</element-citation></ref><ref id="B10-pharmaceutics-17-00175"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heng</surname><given-names>W.</given-names></name>
<name><surname>Song</surname><given-names>Y.</given-names></name>
<name><surname>Luo</surname><given-names>M.</given-names></name>
<name><surname>Hu</surname><given-names>E.</given-names></name>
<name><surname>Wei</surname><given-names>Y.</given-names></name>
<name><surname>Gao</surname><given-names>Y.</given-names></name>
<name><surname>Pang</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Qian</surname><given-names>S.</given-names></name>
</person-group><article-title>Mechanistic insights into the crystallization of coamorphous drug systems</article-title><source>J. Control Release</source><year>2023</year><volume>354</volume><fpage>489</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2023.01.019</pub-id><pub-id pub-id-type="pmid">36646287</pub-id>
</element-citation></ref><ref id="B11-pharmaceutics-17-00175"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Graeser</surname><given-names>K.A.</given-names></name>
<name><surname>Patterson</surname><given-names>J.E.</given-names></name>
<name><surname>Zeitler</surname><given-names>J.A.</given-names></name>
<name><surname>Rades</surname><given-names>T.</given-names></name>
</person-group><article-title>The role of configurational entropy in amorphous systems</article-title><source>Pharmaceutics</source><year>2010</year><volume>2</volume><fpage>224</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.3390/pharmaceutics2020224</pub-id><pub-id pub-id-type="pmid">27721353</pub-id>
</element-citation></ref><ref id="B12-pharmaceutics-17-00175"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chuang</surname><given-names>L.</given-names></name>
<name><surname>Panyoyai</surname><given-names>N.</given-names></name>
<name><surname>Katopo</surname><given-names>L.</given-names></name>
<name><surname>Shanks</surname><given-names>R.</given-names></name>
<name><surname>Kasapis</surname><given-names>S.</given-names></name>
</person-group><article-title>Calcium chloride effects on the glass transition of condensed systems of potato starch</article-title><source>Food Chem.</source><year>2016</year><volume>199</volume><fpage>791</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1016/j.foodchem.2015.12.076</pub-id><pub-id pub-id-type="pmid">26776036</pub-id>
</element-citation></ref><ref id="B13-pharmaceutics-17-00175"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mascia</surname><given-names>L.</given-names></name>
<name><surname>Kouparitsas</surname><given-names>Y.</given-names></name>
<name><surname>Nocita</surname><given-names>D.</given-names></name>
<name><surname>Bao</surname><given-names>X.</given-names></name>
</person-group><article-title>Antiplasticization of polymer materials: Structural aspects and effects on mechanical and diffusion-controlled properties</article-title><source>Polymers</source><year>2020</year><volume>12</volume><elocation-id>769</elocation-id><pub-id pub-id-type="doi">10.3390/polym12040769</pub-id><pub-id pub-id-type="pmid">32244603</pub-id>
</element-citation></ref><ref id="B14-pharmaceutics-17-00175"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Newman</surname><given-names>A.</given-names></name>
<name><surname>Zografi</surname><given-names>G.</given-names></name>
</person-group><article-title>An Examination of Water Vapor Sorption by Multicomponent Crystalline and Amorphous Solids and Its Effects on Their Solid-State Properties</article-title><source>J. Pharm. Sci.</source><year>2019</year><volume>108</volume><fpage>1061</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2018.10.038</pub-id><pub-id pub-id-type="pmid">30391302</pub-id>
</element-citation></ref><ref id="B15-pharmaceutics-17-00175"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hancock</surname><given-names>B.C.</given-names></name>
<name><surname>Zografi</surname><given-names>G.</given-names></name>
</person-group><article-title>The relationship between the glass transition temperature and the water content of amorphous pharmaceutical solids</article-title><source>Pharm. Res.</source><year>1994</year><volume>11</volume><fpage>471</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1023/A:1018941810744</pub-id><pub-id pub-id-type="pmid">8058600</pub-id>
</element-citation></ref><ref id="B16-pharmaceutics-17-00175"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heljo</surname><given-names>V.P.</given-names></name>
<name><surname>Nordberg</surname><given-names>A.</given-names></name>
<name><surname>Tenho</surname><given-names>M.</given-names></name>
<name><surname>Virtanen</surname><given-names>T.</given-names></name>
<name><surname>Jouppila</surname><given-names>K.</given-names></name>
<name><surname>Salonen</surname><given-names>J.</given-names></name>
<name><surname>Maunu</surname><given-names>S.L.</given-names></name>
<name><surname>Juppo</surname><given-names>A.M.</given-names></name>
</person-group><article-title>The effect of water plasticization on the molecular mobility and crystallization tendency of amorphous disaccharides</article-title><source>Pharm. Res.</source><year>2012</year><volume>29</volume><fpage>2684</fpage><lpage>2697</lpage><pub-id pub-id-type="doi">10.1007/s11095-011-0658-4</pub-id><pub-id pub-id-type="pmid">22203327</pub-id>
</element-citation></ref><ref id="B17-pharmaceutics-17-00175"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ruiz</surname><given-names>G.N.</given-names></name>
<name><surname>Romanini</surname><given-names>M.A.-O.X.</given-names></name>
<name><surname>Hauptmann</surname><given-names>A.</given-names></name>
<name><surname>Loerting</surname><given-names>T.</given-names></name>
<name><surname>Shalaev</surname><given-names>E.</given-names></name>
<name><surname>Tamarit</surname><given-names>J.A.-O.</given-names></name>
<name><surname>Pardo</surname><given-names>L.A.-O.</given-names></name>
<name><surname>Macovez</surname><given-names>R.A.-O.</given-names></name>
</person-group><article-title>Genuine antiplasticizing effect of water on a glass-former drug</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>7470</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-07643-5</pub-id><pub-id pub-id-type="pmid">28785030</pub-id>
</element-citation></ref><ref id="B18-pharmaceutics-17-00175"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Grohganz</surname><given-names>H.</given-names></name>
<name><surname>Rades</surname><given-names>T.</given-names></name>
</person-group><article-title>Influence of water on amorphous lidocaine</article-title><source>Mol. Pharm.</source><year>2022</year><volume>19</volume><fpage>3199</fpage><lpage>3205</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.2c00339</pub-id><pub-id pub-id-type="pmid">35876141</pub-id>
</element-citation></ref><ref id="B19-pharmaceutics-17-00175"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Tang</surname><given-names>T.</given-names></name>
<name><surname>Ayranci</surname><given-names>C.</given-names></name>
</person-group><article-title>Moisture-induced anti-plasticization of polylactic acid: Experiments and modeling</article-title><source>J. Appl. Polym. Sci.</source><year>2022</year><volume>139</volume><fpage>52369</fpage><pub-id pub-id-type="doi">10.1002/app.52369</pub-id></element-citation></ref><ref id="B20-pharmaceutics-17-00175"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>J.L.</given-names></name>
<name><surname>Cheng</surname><given-names>F.</given-names></name>
<name><surname>Zhu</surname><given-names>P.X.</given-names></name>
</person-group><article-title>Structure and properties of urea-plasticized starch films with different urea contents</article-title><source>Carbohydr. Polym.</source><year>2014</year><volume>101</volume><fpage>1109</fpage><lpage>1115</lpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2013.10.050</pub-id><pub-id pub-id-type="pmid">24299881</pub-id>
</element-citation></ref><ref id="B21-pharmaceutics-17-00175"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lerbret</surname><given-names>A.</given-names></name>
<name><surname>Affouard</surname><given-names>F.</given-names></name>
</person-group><article-title>Molecular Packing, Hydrogen bonding, and fast dynamics in lysozyme/trehalose/glycerol and trehalose/glycerol glasses at low hydration</article-title><source>J. Phys. Chem. B</source><year>2017</year><volume>121</volume><fpage>9437</fpage><lpage>9451</lpage><pub-id pub-id-type="doi">10.1021/acs.jpcb.7b07082</pub-id><pub-id pub-id-type="pmid">28920435</pub-id>
</element-citation></ref><ref id="B22-pharmaceutics-17-00175"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Rades</surname><given-names>T.</given-names></name>
<name><surname>Grohganz</surname><given-names>H.</given-names></name>
</person-group><article-title>Molecular interactions of hydrated co-amorphous systems of prilocaine and lidocaine</article-title><source>Int. J. Pharm.</source><year>2024</year><volume>651</volume><elocation-id>123807</elocation-id><pub-id pub-id-type="doi">10.1016/j.ijpharm.2024.123807</pub-id><pub-id pub-id-type="pmid">38220121</pub-id>
</element-citation></ref><ref id="B23-pharmaceutics-17-00175"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Grohganz</surname><given-names>H.</given-names></name>
<name><surname>Rades</surname><given-names>T.</given-names></name>
</person-group><article-title>Anti-plasticizing effect of water on prilocaine and lidocaine&#x02014;The role of the hydrogen bonding pattern</article-title><source>Phys. Chem. Chem. Phys.</source><year>2024</year><volume>26</volume><fpage>14149</fpage><lpage>14159</lpage><pub-id pub-id-type="doi">10.1039/D4CP00995A</pub-id><pub-id pub-id-type="pmid">38712380</pub-id>
</element-citation></ref><ref id="B24-pharmaceutics-17-00175"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Rades</surname><given-names>T.</given-names></name>
<name><surname>Grohganz</surname><given-names>H.</given-names></name>
</person-group><article-title>Thermal investigation on hydrated co-amorphous systems of nicotinamide and prilocaine</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2023</year><volume>186</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2023.02.015</pub-id><pub-id pub-id-type="pmid">36878408</pub-id>
</element-citation></ref><ref id="B25-pharmaceutics-17-00175"><label>25.</label><element-citation publication-type="webpage"><article-title>Flurbiprofen. SCIFINDER. American Chemical Society. n.d. (CAS RN: 5104-49-4)</article-title><comment>Available online: <ext-link xlink:href="https://scifinder-n.cas.org/searchDetail/substance/66ab53ab990d45148c8b114f/substanceDetails" ext-link-type="uri">https://scifinder-n.cas.org/searchDetail/substance/66ab53ab990d45148c8b114f/substanceDetails</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-08-01">(accessed on 1 August 2024)</date-in-citation></element-citation></ref><ref id="B26-pharmaceutics-17-00175"><label>26.</label><element-citation publication-type="webpage"><article-title>Lidocaine. SCIFINDER. American Chemical Society. n.d. (CAS RN: 137-58-6)</article-title><comment>Available online: <ext-link xlink:href="https://scifinder-n.cas.org/searchDetail/substance/66ab5441990d45148c8b1f9d/substanceDetails" ext-link-type="uri">https://scifinder-n.cas.org/searchDetail/substance/66ab5441990d45148c8b1f9d/substanceDetails</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-08-01">(accessed on 1 August 2024)</date-in-citation></element-citation></ref><ref id="B27-pharmaceutics-17-00175"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Childs</surname><given-names>S.L.</given-names></name>
<name><surname>Stahly</surname><given-names>G.P.</given-names></name>
<name><surname>Park</surname><given-names>A.</given-names></name>
</person-group><article-title>The salt-cocrystal continuum: The influence of crystal structure on ionization state</article-title><source>Mol. Pharm.</source><year>2007</year><volume>4</volume><fpage>323</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1021/mp0601345</pub-id><pub-id pub-id-type="pmid">17461597</pub-id>
</element-citation></ref><ref id="B28-pharmaceutics-17-00175"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moreira</surname><given-names>D.N.</given-names></name>
<name><surname>Fresno</surname><given-names>N.</given-names></name>
<name><surname>P&#x000e9;rez-Fern&#x000e1;ndez</surname><given-names>R.</given-names></name>
<name><surname>Frizzo</surname><given-names>C.P.</given-names></name>
<name><surname>Goya</surname><given-names>P.</given-names></name>
<name><surname>Marco</surname><given-names>C.</given-names></name>
<name><surname>Martins</surname><given-names>M.A.P.</given-names></name>
<name><surname>Elguero</surname><given-names>J.</given-names></name>
</person-group><article-title>Br&#x000f8;nsted acid&#x02013;base pairs of drugs as dual ionic liquids: NMR ionicity studies</article-title><source>Tetrahedron</source><year>2015</year><volume>71</volume><fpage>676</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1016/j.tet.2014.12.003</pub-id></element-citation></ref><ref id="B29-pharmaceutics-17-00175"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Gurau</surname><given-names>G.</given-names></name>
<name><surname>Shamshina</surname><given-names>J.</given-names></name>
<name><surname>Cojocaru</surname><given-names>O.A.</given-names></name>
<name><surname>Janikowski</surname><given-names>J.</given-names></name>
<name><surname>MacFarlane</surname><given-names>D.R.</given-names></name>
<name><surname>Davis</surname><given-names>J.H.</given-names></name>
<name><surname>Rogers</surname><given-names>R.D.</given-names></name>
</person-group><article-title>Simultaneous membrane transport of two active pharmaceutical ingredients by charge assisted hydrogen bond complex formation</article-title><source>Chem. Sci.</source><year>2014</year><volume>5</volume><fpage>3449</fpage><lpage>3456</lpage><pub-id pub-id-type="doi">10.1039/C4SC01036A</pub-id></element-citation></ref><ref id="B30-pharmaceutics-17-00175"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marei</surname><given-names>H.F.</given-names></name>
<name><surname>Arafa</surname><given-names>M.F.</given-names></name>
<name><surname>Essa</surname><given-names>E.A.</given-names></name>
<name><surname>El Maghraby</surname><given-names>G.M.</given-names></name>
</person-group><article-title>Lidocaine as eutectic forming drug for enhanced transdermal delivery of nonsteroidal anti-inflammatory drugs</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2021</year><volume>61</volume><elocation-id>102338</elocation-id><pub-id pub-id-type="doi">10.1016/j.jddst.2021.102338</pub-id></element-citation></ref><ref id="B31-pharmaceutics-17-00175"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fiandaca</surname><given-names>M.</given-names></name>
<name><surname>Dalwadi</surname><given-names>G.</given-names></name>
<name><surname>Wigent</surname><given-names>R.</given-names></name>
<name><surname>Gupta</surname><given-names>P.</given-names></name>
</person-group><article-title>Ionic liquid formation with deep eutectic forces at an atypical ratio (2:1) of naproxen to lidocaine in the solid-state, thermal characterization and FTIR investigation</article-title><source>Int. J. Pharm.</source><year>2020</year><volume>575</volume><elocation-id>118946</elocation-id><pub-id pub-id-type="doi">10.1016/j.ijpharm.2019.118946</pub-id><pub-id pub-id-type="pmid">31837407</pub-id>
</element-citation></ref><ref id="B32-pharmaceutics-17-00175"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Blaabjerg</surname><given-names>L.I.</given-names></name>
<name><surname>Lindenberg</surname><given-names>E.</given-names></name>
<name><surname>L&#x000f6;bmann</surname><given-names>K.</given-names></name>
<name><surname>Grohganz</surname><given-names>H.</given-names></name>
<name><surname>Rades</surname><given-names>T.</given-names></name>
</person-group><article-title>Glass Forming Ability of Amorphous Drugs Investigated by Continuous Cooling and Isothermal Transformation</article-title><source>Mol. Pharm.</source><year>2016</year><volume>13</volume><fpage>3318</fpage><lpage>3325</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.6b00650</pub-id><pub-id pub-id-type="pmid">27529364</pub-id>
</element-citation></ref><ref id="B33-pharmaceutics-17-00175"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Toda</surname><given-names>A.</given-names></name>
<name><surname>Arita</surname><given-names>T.</given-names></name>
<name><surname>Tomita</surname><given-names>C.</given-names></name>
<name><surname>Hikosaka</surname><given-names>M.</given-names></name>
</person-group><article-title>Temperature-modulated DSC applied to the transformation kinetics of polymer crystallization</article-title><source>Polym. J.</source><year>1999</year><volume>31</volume><fpage>790</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1295/polymj.31.790</pub-id></element-citation></ref><ref id="B34-pharmaceutics-17-00175"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pak</surname><given-names>J.</given-names></name>
<name><surname>Wunderlich</surname><given-names>B.</given-names></name>
</person-group><article-title>Melting and crystallization of polyethylene of different molar mass by calorimetry</article-title><source>Macromolecules</source><year>2001</year><volume>34</volume><fpage>4492</fpage><lpage>4503</lpage><pub-id pub-id-type="doi">10.1021/ma010195a</pub-id></element-citation></ref><ref id="B35-pharmaceutics-17-00175"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Righetti</surname><given-names>M.C.</given-names></name>
<name><surname>Prevosto</surname><given-names>D.</given-names></name>
<name><surname>Tombari</surname><given-names>E.</given-names></name>
</person-group><article-title>Time and temperature evolution of the rigid amorphous fraction and differently constrained amorphous fractions in PLLA</article-title><source>Macromol. Chem. Phys.</source><year>2016</year><volume>217</volume><fpage>2013</fpage><lpage>2026</lpage><pub-id pub-id-type="doi">10.1002/macp.201600210</pub-id></element-citation></ref><ref id="B36-pharmaceutics-17-00175"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Righetti</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Crystallization of polymers investigated by temperature-modulated DSC</article-title><source>Materials</source><year>2017</year><volume>10</volume><elocation-id>442</elocation-id><pub-id pub-id-type="doi">10.3390/ma10040442</pub-id><pub-id pub-id-type="pmid">28772807</pub-id>
</element-citation></ref><ref id="B37-pharmaceutics-17-00175"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Otun</surname><given-names>S.O.</given-names></name>
<name><surname>Meehan</surname><given-names>E.</given-names></name>
<name><surname>Qi</surname><given-names>S.</given-names></name>
<name><surname>Craig</surname><given-names>D.Q.</given-names></name>
</person-group><article-title>The use of quasi-isothermal modulated temperature differential scanning calorimetry for the characterization of slow crystallization processes in lipid-based solid self-emulsifying systems</article-title><source>Pharm. Res.</source><year>2015</year><volume>32</volume><fpage>1316</fpage><lpage>1324</lpage><pub-id pub-id-type="doi">10.1007/s11095-014-1535-8</pub-id><pub-id pub-id-type="pmid">25330742</pub-id>
</element-citation></ref><ref id="B38-pharmaceutics-17-00175"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Svoboda</surname><given-names>R.</given-names></name>
</person-group><article-title>Crystallization of glasses&#x02014;When to use the Johnson-Mehl-Avrami kinetics?</article-title><source>J. Eur. Ceram. Soc.</source><year>2021</year><volume>41</volume><fpage>7862</fpage><lpage>7867</lpage><pub-id pub-id-type="doi">10.1016/j.jeurceramsoc.2021.08.026</pub-id></element-citation></ref><ref id="B39-pharmaceutics-17-00175"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kramarczyk</surname><given-names>D.</given-names></name>
<name><surname>Knapik-Kowalczuk</surname><given-names>J.</given-names></name>
<name><surname>Smolka</surname><given-names>W.</given-names></name>
<name><surname>Monteiro</surname><given-names>M.F.</given-names></name>
<name><surname>Tajber</surname><given-names>L.</given-names></name>
<name><surname>Paluch</surname><given-names>M.</given-names></name>
</person-group><article-title>Inhibition of celecoxib crystallization by mesoporous silica&#x02014;Molecular dynamics studies leading to the discovery of the stabilization origin</article-title><source>Eur. J. Pharm. Sci.</source><year>2022</year><volume>171</volume><elocation-id>106132</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejps.2022.106132</pub-id><pub-id pub-id-type="pmid">35077845</pub-id>
</element-citation></ref><ref id="B40-pharmaceutics-17-00175"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Knapik-Kowalczuk</surname><given-names>J.</given-names></name>
<name><surname>Rams-Baron</surname><given-names>M.</given-names></name>
<name><surname>Paluch</surname><given-names>M.</given-names></name>
</person-group><article-title>Current research trends in dielectric relaxation studies of amorphous pharmaceuticals: Physical stability, tautomerism, and the role of hydrogen bonding</article-title><source>TrAC Trends Anal. Chem.</source><year>2021</year><volume>134</volume><elocation-id>116097</elocation-id><pub-id pub-id-type="doi">10.1016/j.trac.2020.116097</pub-id></element-citation></ref><ref id="B41-pharmaceutics-17-00175"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Androsch</surname><given-names>R.</given-names></name>
<name><surname>Wunderlich</surname><given-names>B.</given-names></name>
</person-group><article-title>Specific reversible melting of polymers</article-title><source>J. Polym. Sci. Part B Polym. Phys.</source><year>2003</year><volume>41</volume><fpage>2039</fpage><lpage>2051</lpage><pub-id pub-id-type="doi">10.1002/polb.10573</pub-id></element-citation></ref><ref id="B42-pharmaceutics-17-00175"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhugra</surname><given-names>C.</given-names></name>
<name><surname>Pikal</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state</article-title><source>J. Pharm. Sci.</source><year>2008</year><volume>97</volume><fpage>1329</fpage><lpage>1349</lpage><pub-id pub-id-type="doi">10.1002/jps.21138</pub-id><pub-id pub-id-type="pmid">17722100</pub-id>
</element-citation></ref><ref id="B43-pharmaceutics-17-00175"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Avrami</surname><given-names>M.</given-names></name>
</person-group><article-title>Kinetics of Phase Change. I General Theory</article-title><source>J. Chem. Phys.</source><year>1939</year><volume>7</volume><fpage>1103</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1063/1.1750380</pub-id></element-citation></ref><ref id="B44-pharmaceutics-17-00175"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Avrami</surname><given-names>M.</given-names></name>
</person-group><article-title>Kinetics of Phase Change. II Transformation-Time Relations for Random Distribution of Nuclei</article-title><source>J. Chem. Phys.</source><year>1940</year><volume>8</volume><fpage>212</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1063/1.1750631</pub-id></element-citation></ref><ref id="B45-pharmaceutics-17-00175"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Avrami</surname><given-names>M.</given-names></name>
</person-group><article-title>Granulation, Phase Change, and Microstructure Kinetics of Phase Change. III</article-title><source>J. Chem. Phys.</source><year>1941</year><volume>9</volume><fpage>177</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1063/1.1750872</pub-id></element-citation></ref><ref id="B46-pharmaceutics-17-00175"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Havriliak</surname><given-names>S.</given-names></name>
<name><surname>Negami</surname><given-names>S.</given-names></name>
</person-group><article-title>A complex plane representation of dielectric and mechanical relaxation processes in some polymers</article-title><source>Polymer</source><year>1967</year><volume>8</volume><fpage>161</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/0032-3861(67)90021-3</pub-id></element-citation></ref><ref id="B47-pharmaceutics-17-00175"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fulcher</surname><given-names>G.S.</given-names></name>
</person-group><article-title>Analysis of recent measurements of the viscosity of glasses</article-title><source>J. Am. Ceram. Soc.</source><year>1925</year><volume>8</volume><fpage>339</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1111/j.1151-2916.1925.tb16731.x</pub-id></element-citation></ref><ref id="B48-pharmaceutics-17-00175"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fox</surname><given-names>T.G.</given-names><suffix>Jr.</suffix></name>
<name><surname>Flory</surname><given-names>P.J.</given-names></name>
</person-group><article-title>Second-Order Transition Temperatures and Related Properties of Polystyrene. I. Influence of Molecular Weight</article-title><source>J. Appl. Phys.</source><year>1950</year><volume>21</volume><fpage>581</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1063/1.1699711</pub-id></element-citation></ref><ref id="B49-pharmaceutics-17-00175"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>S.</given-names></name>
<name><surname>McKenna</surname><given-names>G.B.</given-names></name>
</person-group><article-title>Isothermal crystallization and time-temperature transformation of amorphous nifedipine: A case of polymorphism formation and conversion</article-title><source>Mol. Pharm.</source><year>2021</year><volume>18</volume><fpage>2786</fpage><lpage>2802</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.1c00331</pub-id><pub-id pub-id-type="pmid">34105978</pub-id>
</element-citation></ref><ref id="B50-pharmaceutics-17-00175"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ruiz</surname><given-names>G.N.</given-names></name>
<name><surname>Romanini</surname><given-names>M.</given-names></name>
<name><surname>Barrio</surname><given-names>M.</given-names></name>
<name><surname>Tamarit</surname><given-names>J.L.</given-names></name>
<name><surname>Pardo</surname><given-names>L.C.</given-names></name>
<name><surname>Macovez</surname><given-names>R.</given-names></name>
</person-group><article-title>Relaxation dynamics vs crystallization kinetics in the amorphous state: The case of stiripentol</article-title><source>Mol. Pharm.</source><year>2017</year><volume>14</volume><fpage>3636</fpage><lpage>3643</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.7b00399</pub-id><pub-id pub-id-type="pmid">28915351</pub-id>
</element-citation></ref><ref id="B51-pharmaceutics-17-00175"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Madbouly</surname><given-names>S.A.</given-names></name>
<name><surname>Mansour</surname><given-names>A.A.</given-names></name>
<name><surname>Abdou</surname><given-names>N.Y.</given-names></name>
</person-group><article-title>Crystallization kinetics of PHB/PVAc blends using time resolved dielectric spectroscopy</article-title><source>Eur. Polym. J.</source><year>2007</year><volume>43</volume><fpage>3933</fpage><lpage>3942</lpage><pub-id pub-id-type="doi">10.1016/j.eurpolymj.2007.06.020</pub-id></element-citation></ref><ref id="B52-pharmaceutics-17-00175"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pirayavaraporn</surname><given-names>C.</given-names></name>
<name><surname>Rades</surname><given-names>T.</given-names></name>
<name><surname>Gordon</surname><given-names>K.C.</given-names></name>
<name><surname>Tucker</surname><given-names>I.G.</given-names></name>
</person-group><article-title>Quantification of the types of water in Eudragit RLPO polymer and the kinetics of water loss using FTIR</article-title><source>Int. J. Pharm.</source><year>2013</year><volume>458</volume><fpage>90</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2013.10.012</pub-id><pub-id pub-id-type="pmid">24144952</pub-id>
</element-citation></ref><ref id="B53-pharmaceutics-17-00175"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Inoue</surname><given-names>T.</given-names></name>
</person-group><article-title>Effect of water on melting phase relations and melt composition in the system Mg<sub>2</sub>SiO<sub>4</sub>&#x000b7;MgSiO<sub>3</sub>&#x000b7;H<sub>2</sub>O up to 15 GPa</article-title><source>Phys. Earth Planet. Inter.</source><year>1994</year><volume>85</volume><fpage>237</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1016/0031-9201(94)90116-3</pub-id></element-citation></ref><ref id="B54-pharmaceutics-17-00175"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>D.</given-names></name>
<name><surname>Zhang</surname><given-names>G.G.</given-names></name>
<name><surname>Law</surname><given-names>D.</given-names></name>
<name><surname>Grant</surname><given-names>D.J.</given-names></name>
<name><surname>Schmitt</surname><given-names>E.A.</given-names></name>
</person-group><article-title>Thermodynamics, molecular mobility and crystallization kinetics of amorphous griseofulvin</article-title><source>Mol. Pharm.</source><year>2008</year><volume>5</volume><fpage>927</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1021/mp800169g</pub-id><pub-id pub-id-type="pmid">19434849</pub-id>
</element-citation></ref><ref id="B55-pharmaceutics-17-00175"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lauritzen</surname><given-names>J.I.</given-names><suffix>Jr.</suffix></name>
<name><surname>Hoffman</surname><given-names>J.D.</given-names></name>
</person-group><article-title>Theory of formation of polymer crystals with folded chains in dilute solution</article-title><source>J. Res. Natl. Bur. Stand. A Phys. Chem.</source><year>1960</year><volume>64</volume><fpage>73</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.6028/jres.064A.007</pub-id><pub-id pub-id-type="pmid">32196159</pub-id>
</element-citation></ref><ref id="B56-pharmaceutics-17-00175"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qian</surname><given-names>K.K.</given-names></name>
<name><surname>Bogner</surname><given-names>R.H.</given-names></name>
</person-group><article-title>Application of mesoporous silicon dioxide and silicate in oral amorphous drug delivery systems</article-title><source>J. Pharm. Sci.</source><year>2012</year><volume>101</volume><fpage>444</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1002/jps.22779</pub-id><pub-id pub-id-type="pmid">21976048</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-17-00175-f001"><label>Figure 1</label><caption><p>XRPD diffractograms of anhydrous co-amorphous FLB-LID systems with mole fractions of LID from 0.1 to 0.9.</p></caption><graphic xlink:href="pharmaceutics-17-00175-g001" position="float"/></fig><fig position="float" id="pharmaceutics-17-00175-f002"><label>Figure 2</label><caption><p>XRPD diffractograms of co-amorphous FLB-LID with X<sub>H2O</sub> = 0%, 10%, 50% after isothermal partial crystallization, crystalline FLB, and crystalline LID.</p></caption><graphic xlink:href="pharmaceutics-17-00175-g002" position="float"/></fig><fig position="float" id="pharmaceutics-17-00175-f003"><label>Figure 3</label><caption><p>Crystallization fractions of anhydrous and hydrated co-amorphous FLB-LID systems with water-to-drug molar ratios of X<sub>H2O</sub> = 0%, X<sub>H2O</sub> = 10%, and X<sub>H2O</sub> = 50%, as a function of time upon isothermal crystallization at 251 K (<bold>A</bold>), 249 K (<bold>B</bold>), and 245 K (<bold>C</bold>). The JMA fitting results are shown as black dashed lines.</p></caption><graphic xlink:href="pharmaceutics-17-00175-g003" position="float"/></fig><fig position="float" id="pharmaceutics-17-00175-f004"><label>Figure 4</label><caption><p>DSC thermograms of anhydrous and hydrated co-amorphous FLB-LID systems with water-to-drug molar ratios of X<sub>H2O</sub> = 0% (<bold>A</bold>), X<sub>H2O</sub> = 10% (<bold>B</bold>), and X<sub>H2O</sub> = 50% (<bold>C</bold>) upon isothermal partial crystallization at 251 K (lines), 249 K (dashed lines), and 245 K (dots).</p></caption><graphic xlink:href="pharmaceutics-17-00175-g004" position="float"/></fig><fig position="float" id="pharmaceutics-17-00175-f005"><label>Figure 5</label><caption><p>Temperature dependence of &#x003b1;-relaxation times of anhydrous and hydrated co-amorphous FLB-LID systems with water-to-drug molar ratios of X<sub>H2O</sub> = 0% (green), X<sub>H2O</sub> = 10% (orange), and X<sub>H2O</sub> = 50% (purple). The VFT fitting results are shown as dashed lines in the corresponding colors.</p></caption><graphic xlink:href="pharmaceutics-17-00175-g005" position="float"/></fig><fig position="float" id="pharmaceutics-17-00175-f006"><label>Figure 6</label><caption><p>Temperature dependence of &#x00394;G (<bold>A</bold>), &#x00394;S (<bold>B</bold>), and (T&#x00394;S)<sup>3</sup>/&#x00394;G<sup>2</sup> (<bold>C</bold>) of anhydrous and hydrated co-amorphous FLB-LID systems with water-to-drug molar ratios of X<sub>H2O</sub> = 0% (green), X<sub>H2O</sub> = 10% (orange), and X<sub>H2O</sub> = 50% (purple).</p></caption><graphic xlink:href="pharmaceutics-17-00175-g006" position="float"/></fig><table-wrap position="float" id="pharmaceutics-17-00175-t001"><object-id pub-id-type="pii">pharmaceutics-17-00175-t001_Table 1</object-id><label>Table 1</label><caption><p>Crystallization fractions, complete-time, and JMA fitting parameters of anhydrous and hydrated co-amorphous FLB-LID systems with X<sub>H2O</sub> = 0%, X<sub>H2O</sub> = 10%, and X<sub>H2O</sub> = 50%.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Temperature</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">X<sub>H2O</sub></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Crystallization<break/>Fraction</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Crystallization<break/>Complete-Time [min]</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">n</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">k [min<sup>&#x02212;1</sup>]</th></tr></thead><tbody><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">251 K</td><td align="center" valign="middle" rowspan="1" colspan="1">0%</td><td align="center" valign="middle" rowspan="1" colspan="1">66.1%</td><td align="center" valign="middle" rowspan="1" colspan="1">136.7</td><td align="center" valign="middle" rowspan="1" colspan="1">2.11</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0094</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10%</td><td align="center" valign="middle" rowspan="1" colspan="1">60.1%</td><td align="center" valign="middle" rowspan="1" colspan="1">198.8</td><td align="center" valign="middle" rowspan="1" colspan="1">1.83</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0055</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27.1%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">256.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.51</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0021</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">249 K</td><td align="center" valign="middle" rowspan="1" colspan="1">0%</td><td align="center" valign="middle" rowspan="1" colspan="1">69.0%</td><td align="center" valign="middle" rowspan="1" colspan="1">237.7</td><td align="center" valign="middle" rowspan="1" colspan="1">1.92</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0054</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10%</td><td align="center" valign="middle" rowspan="1" colspan="1">62.6%</td><td align="center" valign="middle" rowspan="1" colspan="1">389.3</td><td align="center" valign="middle" rowspan="1" colspan="1">1.87</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0029</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31.3%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">447.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.54</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0014</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">245 K</td><td align="center" valign="middle" rowspan="1" colspan="1">0%</td><td align="center" valign="middle" rowspan="1" colspan="1">62.9%</td><td align="center" valign="middle" rowspan="1" colspan="1">620.7</td><td align="center" valign="middle" rowspan="1" colspan="1">2.22</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0020</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10%</td><td align="center" valign="middle" rowspan="1" colspan="1">60.0%</td><td align="center" valign="middle" rowspan="1" colspan="1">897.0</td><td align="center" valign="middle" rowspan="1" colspan="1">1.88</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0011</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39.3%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1476.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.54</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0005</td></tr></tbody></table></table-wrap></floats-group></article>